Drugs Manufacturer from Hyderabad on overdrive

Optimus Pharma gets DCGI nod for conducting Phase III Clinical Trials for Molnupiravir on patients with mild and moderate COVID-19 infection

Hyderabad (Telangana) [India], May 19: Optimus Pharma on Tuesday received DCGI nod for conducting Phase III Clinical Trials for orally administered Molnupiravir capsules on patients with Mild and Moderate Covid-19 symptoms. With a severe shortage of antiviral drugs in the market against the SARS-CoV-2 infection, it is imperative that more drugs with potent antiviral activity against SARS-CoV-2 be introduced.

Optimus pharma said having internally developed the active pharmaceutical ingredient (API) and the formulations for the product, it had filed for clinical trials with the DCGI. The regulator gave a nod for conducting the trial on mild and moderate patients on May 18 2021.

As per the clinical trial, protocols approved, a total of 2500 subjects in both mild and moderate COVID-19 will be randomised in the study in a 1:1 ratio to Molnupiravir with standard supportive care or standalone standard supportive care. The treatment duration is a maximum of 05 days and the total study duration will be a maximum for 29 days from randomisation, the release said.

“Optimus is all geared to immediately begin clinical trials on Molnupiravir on COVID-19 patients in India. The clinical trial will let us know the efficacy of this molecule on COVID-19 patients,” Chairman & Managing Director – Dr. D Srinivas Reddy said.

In the previous press release, the company stated that Molnupiravir demonstrated highly promising results in reducing viral load to 0.0% in merely 5 days of treatment duration. Based on completed phase 2 part clinical studies, the proposed dosage is 800mg twice daily which significantly reduces viral culture in infected patients not progressing into ARDS.

Optimus Pharma is one of the largest manufacturers of the highly successful SARS-CoV-2 antiviral drug without compromising on quality as is the case with Favipiravir (sold under the brand – FAVICOVID).  The company aims to do the same with Molnupiravir to cater to the rising demand for Anti-Viral drugs against SARS-CoV-2 in the Indian market.

With the cooperation of the government and our stakeholders, and a special thanks to the Subject Expert Committee of the CDSCO for their valuable contribution and their recommendations to the project, we hope to deliver the product in India by leveraging our solid distribution strength across the country.

Leave a Reply

Your email address will not be published. Required fields are marked *

Health

On the eve of World Cancer Day, Global Healthcare Advisor Vijay Dhawangale shares his views on awareness in the fight against cancer

Read Time:4 Minute, 5 Second Vijay Dhawangale, a global healthcare advisor, offers his thoughts on raising awareness against cancer Mumbai (Maharashtra) [India], February 3: World Cancer Day is held every year on 4 February to raise worldwide awareness in the fight against cancer. The three most commonly occurring cancers in India are those of the breast, uterine cervix, […]

Read More
Health

Revolutionary i-Align technique simplifies joint replacement with minimal invasion and best outcome: Dr. Pratul Jain

Read Time:3 Minute, 31 Second February 1: “Excruciating pain, the long recovery process, and fat operation costs are major concerns of people suffering from issues related to joint pain in their bodies,” says Dr. Pratul Jain, Director &senior orthopedic and joint replacement surgeon of Ginni Devi Hospital – Jaipur, Rajasthan. In his career spanning decades, […]

Read More
Health

Introducing MOI: India’s only Tens + Heating Device For Period Pain

Read Time:2 Minute, 44 Second MOI: India’s only Tens + Heating Device For Period Pain India’s First & Only TENS + Heating Period Pain Relief Device Truly Wireless, Wearable & On-the-go Use 100% Drug-free, Zero Side Effects, and Skin-friendly New Delhi (India), January 27: “Life doesn’t stop during PMS, so why should you?” With this […]

Read More